Ixekizumab May Improve Renal Function in Psoriasis.

Autor:	Amoruso GF; Unit of Dermatology, Mariano Santo Hospital, 87100 Cosenza, Italy., Nisticò SP; Unit of Dermatology, Department of Health Sciences, Magna Graecia University, Viale Europa SNC, 88100 Catanzaro, Italy., Iannone L; Unit of Dermatology, Department of Health Sciences, Magna Graecia University, Viale Europa SNC, 88100 Catanzaro, Italy., Russo E; Unit of Dermatology, Department of Health Sciences, Magna Graecia University, Viale Europa SNC, 88100 Catanzaro, Italy., Rago G; COVID Pneumology Unit, Ospedale di Rossano, 87067 Rossano, Italy., Patruno C; Unit of Dermatology, Department of Health Sciences, Magna Graecia University, Viale Europa SNC, 88100 Catanzaro, Italy., Bennardo L; Unit of Dermatology, Department of Health Sciences, Magna Graecia University, Viale Europa SNC, 88100 Catanzaro, Italy.
Jazyk:	angličtina
Zdroj:	Healthcare (Basel, Switzerland) [Healthcare (Basel)] 2021 May 07; Vol. 9 (5). Date of Electronic Publication: 2021 May 07.
DOI:	10.3390/healthcare9050543
Abstrakt:	Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case Report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions. Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu